GRI:ARCA-Cohen & Steers Global Realty Majors (USD)

ETF | Biotechnology | NYSE Arca

Last Closing

USD 0.4007

Change

0.00 (-1.18)%

Market Cap

USD 0.09B

Volume

0.11M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks investment results that correspond generally to the performance, before the fund's fees and expenses, of an index called the Cohen & Steers Global Realty Majors Index. The fund will normally invest at least 90% of its total assets in common stocks and other equity securities (which may include ADRs, ADSs and GDRs) that comprise the underlying index. The underlying index consists of the largest and most liquid securities within the global real estate universe that the index provider believes are likely to lead the global securitization of real estate. The fund is non-diversified.

Inception Date: 07/05/2008

Primary Benchmark: Cohen & Steers Gbl Realty Majr TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.55%

Management Expense Ratio: 0.55 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Biotechnology

Symbol Name Mer Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc 0.00 %

+4.72 (+1.00%)

USD 121.32B
REGN Regeneron Pharmaceuticals Inc 0.00 %

-4.54 (-0.49%)

USD 103.77B
ALNY Alnylam Pharmaceuticals Inc 0.00 %

-3.20 (-1.12%)

USD 36.83B
ARGX argenx NV ADR 0.00 %

-1.17 (-0.21%)

USD 33.21B
BGNE BeiGene Ltd 0.00 %

-10.54 (-4.87%)

USD 24.57B
MRNA Moderna Inc 0.00 %

-0.50 (-0.91%)

USD 20.52B
RPRX Royalty Pharma Plc 0.00 %

+0.04 (+0.15%)

USD 16.47B
UTHR United Therapeutics Corporatio.. 0.00 %

+8.60 (+2.44%)

USD 15.69B
SMMT Summit Therapeutics PLC 0.00 %

-3.18 (-14.57%)

USD 15.13B
PCVX Vaxcyte Inc 0.00 %

+0.55 (+0.52%)

USD 13.95B

ETFs Containing GRI

UKPH:XETRA iShares UK Property UCITS.. 3.23 % 0.00 %

+0.01 (+0.20%)

N/A
UKRE:LSE iShares MSCI Target UK Re.. 2.48 % 0.00 %

+0.05 (+0.20%)

USD 0.12B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -85.13% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.13% 3% F 1% F
Trailing 12 Months  
Capital Gain -99.88% N/A F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.88% N/A F N/A F
Trailing 5 Years  
Capital Gain -99.88% 2% F 1% F
Dividend Return 1.36% 33% F 6% D-
Total Return -98.52% 9% A- 4% F
Average Annual (5 Year Horizon)  
Capital Gain -20.78% 31% F 17% F
Dividend Return -20.71% 31% F 17% F
Total Return 0.07% 22% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 40.24% 67% D+ 44% F
Risk Adjusted Return -51.47% 32% F 20% F
Market Capitalization 0.09B 1% F 1% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector